Oslo, Norway, 9-4-2014 — /EuropaWire/ — Yara International ASA first quarter 2014 results will be released on Wednesday 30 April 2014. The results will be available at www.yara.com from 08:00 CEST.
The results will be presented at 09:30 CEST by President and CEO Jørgen Ole Haslestad and CFO Torgeir Kvidal. The presentation will take place in the Auditorium in Bygdøy allé 2 and will be webcast at www.yara.com. The presentation will be held in English.
There will also be a conference call at 14:00 CEST the same day with an opportunity to ask questions to Yara’s CEO and CFO.
Norway dial-in number +47 21 56 31 20 – conference id: 943792
European dial-in number +44 207 162 0077 – conference id: 943792
US dial-in number +1 334 323 6201 – conference id: 943792
Up to two weeks after the call, you may listen to the replay by calling:
+47 21 50 12 92, code 943792
+44 20 7031 4064, code 943792 or
+1 954 334 0342, code 943792.
If you wish to attend the presentation in Oslo, please register by e-mail to ir@yara.com by 29 April 2014.
Subscribe for press releases: http://www.yara.com/media/press_releases/newsletter/index.aspx
Unsubscribe for press releases: http://www.yara.com/media/press_releases/newsletter/unsubscribe.aspx
Please note that Yara will also present at several roadshows and conferences; these are posted on our financial calendar: http://www.yara.com/investor_relations/financial_calendar/index.aspx
Yours faithfully
for Yara International ASA
Thor Giæver
Head of Investor Relations
(sign.)
This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
(IN BRIEF) Eurex, on April 29, 2024, introduced a new Green Bond Basket within its…
(IN BRIEF) Last Friday, NMB Bank Plc celebrated the listing of its dual-currency sustainability bond,…
(IN BRIEF) CapMan Nordic Infrastructure II fund has reached its final closing at over €375…
(IN BRIEF) AstraZeneca and Daiichi Sankyo's Enhertu, a HER2-directed antibody drug conjugate (ADC), has demonstrated…
(IN BRIEF) AstraZeneca's Truqap, in combination with Faslodex, has received a positive recommendation from the…
(IN BRIEF) Ørsted, a global leader in renewable energy, is divesting its French onshore operations…